Robert Wood's most recent trade in Tscan Therapeutics Inc was a trade of 67,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,050 | 12,050 | - | - | Non-Qualified Stock Option (right to buy) | |
| X4 Pharmaceuticals Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 1,500 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 110,067 | 110,067 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 500,000 | 600,000 (2%) | 1% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Robert Keith Woods | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 482 | 14,495 (0%) | 0% | 0 | Ordinary Shares | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 482 | 0 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 464 | 464 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 470.12 per share. | 07 Mar 2025 | 32 | 14,463 (0%) | 0% | 470.1 | 15,044 | Ordinary Shares |
| Linde | Robert L. Wood | Director | Sale of securities on an exchange or to another person at price $ 456.26 per share. | 10 Feb 2025 | 2,900 | 14,012 (0%) | 0% | 456.3 | 1,323,154 | Ordinary Shares |
| DXC Technology Co | Robert F. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 12,300 | 69,131 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 7,700 | 7,700 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Robert Keith Woods | Director | 13 Jun 2024 | 23,944 | 23,944 | - | - | Stock Option (Right to Buy) | ||
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 135,000 (0%) | 0% | 0 | Common Stock | |
| MRC Global Inc | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 22,288 | 138,517 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 598 | 16,894 (0%) | 0% | 0 | Ordinary Shares | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 598 | 0 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 511.50 per share. | 11 Mar 2024 | 10 | 16,883 (0%) | 0% | 511.5 | 5,115 | Ordinary Shares |
| Linde | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 477 | 477 | - | - | Restricted Stock Units | |
| Neurogene Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 15,400 | 15,400 | - | - | Stock Option (Right to Buy) | |
| Tscan Therapeutics Inc | Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| DXC Technology Co | Robert F. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 12,400 | 56,831 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2023 | 611 | 16,414 (0%) | 0% | 0 | Ordinary Shares | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2023 | 611 | 0 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 591 | 591 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 350.05 per share. | 07 Mar 2023 | 119 | 16,295 (0%) | 0% | 350.1 | 41,656 | Ordinary Shares |
| DXC Technology Co | Robert F. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2022 | 6,300 | 44,431 (0%) | 0% | 0 | Common Stock | |
| MRC Global Inc | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 18,412 | 88,275 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 602 | 602 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 518 | 15,802 (0%) | 0% | 0 | Ordinary Shares | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 518 | 0 | - | - | Restricted Stock Units | |
| DXC Technology Co | Robert F. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 5,600 | 38,131 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 624 | 0 | - | - | Restricted Stock Units | |
| Linde | Robert L. Wood | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 624 | 15,286 (0%) | 0% | 0 | Ordinary Shares | |
| Linde | Robert L. Wood | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.60 per share. | 13 May 2021 | 25 | 15,261 (0%) | 0% | 254.6 | 6,365 | Ordinary Shares |
| MRC Global Inc | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2021 | 13,383 | 69,863 (0%) | 0% | 0 | Common Stock | |
| Linde | Robert L. Wood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 511 | 0 | - | - | Restricted Stock Units | |
| DXC Technology Co | Robert F. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 10,300 | 32,531 (0%) | 0% | 0 | Common Stock |